| Literature DB >> 22666624 |
Abstract
Microglia are multifunctional immune cells in the central nervous system (CNS). In the neurodegenerative diseases such as Alzheimer's disease (AD), accumulation of glial cells, gliosis, occurs in the lesions. The role of accumulated microglia in the pathophysiology of AD is still controversial. When neuronal damage occurs, microglia exert diversified functions, including migration, phagocytosis, and production of various cytokines and chemokines. Among these, microglial phagocytosis of unwanted neuronal debris is critical to maintain the healthy neuronal networks. Microglia express many surface receptors implicated in phagocytosis. It has been suggested that the lack of microglial phagocytosis worsens pathology of AD and induces memory impairment. The present paper summarizes recent evidences on implication of microglial chemotaxis and phagocytosis in AD pathology and discusses the mechanisms related to chemotaxis toward injured neurons and phagocytosis of unnecessary debris.Entities:
Year: 2012 PMID: 22666624 PMCID: PMC3359803 DOI: 10.1155/2012/891087
Source DB: PubMed Journal: Int J Alzheimers Dis
Various chemotaxis or phagocytosis-related receptors in microglia and its ligand(s) or interacted factors. Microglia are activated with various stimuli through the specific receptor of each stimuli. For detailed review of chemokines, pathogens, and factors associated with tissue damage recognized by microglia, refer to [19–21].
| Receptor type | Subtypes | Ligand(s)/interacted factors |
|---|---|---|
| CCR1 | CCL3 (MIP-1 | |
| Chemokine receptor | CCR2 | CCL2 (MCP-1), CCL7 (MCP-3), CCL8 (MCP-2), CCL13 (MCP-4), CCL16 (HCC-4/LEC) |
| CCR5 | CCL3 (MIP-1 | |
| CXCR3 | CXCL9 (Mig), CXCL10 (IP-10), CXCL11 (I-TAC) | |
| CX3CR1 | CX3CL1 (Fractalkine) | |
|
| ||
| Purinergic receptor | P2X4, P2Y7, P2Y12 | ATP, ADP |
|
| ||
| TLR | TLR1 | Triacyl lipopeptides |
|
| ||
| Phosphatidylserine (PS) receptor | MFG-E8, Tim1, Tim4 | PS of apoptotic cells |
|
| ||
| Scavenger receptor (SR) | SR-AI/II (CD204), SR-BI, CD36 | Cellular debris, apoptotic cells, A |
|
| ||
| Immunoglobulin (Ig) receptor | Fc | Ig-opsonized particles |
|
| ||
| Complement receptor (CR) | CR3 (MAC-1; CD11b/CD18) | Complement components, opsonized particles |
|
| ||
| Other phagocytosis-related receptor | CD14 | LPS, A |
Figure 1Chemotaxis or phagocytosis-involved receptors in microglia and correlation of the inflammatory or anti-inflammatory response. Many of the receptors correlated with microglial activities of chemotaxis (migration) or phagocytosis, respectively. Among these, some of the receptors possess not merely single function; CCR1 is the migration-inducing receptor that also possesses phagocytotic activity. CCR2 and CCR5 are also the migration-inducting receptors that lead to anti-inflammatory response. CX3CR1 contributes to migration, phagocytosis, and anti-inflammatory response. TREM2 and MFG-E8 induce phagocytosis and anti-inflammatory response. CD47 and CD200R usually induce phagocytosis under pathological condition, so that they indirectly contribute to anti-inflammatory status. TLR9 activates microglia to induce phagocytosis with producing proinflammatory and anti-inflammatory molecules. There are receptors inducing not only phagocytosis but also inflammatory response (CD14, CD36, RAGE, TLR1, TLR2, TLR4, and TLR6). Within these receptors that the synergistic signaling involved Aβ-triggering inflammatory response are CD14-TLR2-TLR4 and CD36-TLR2-TLR6.
Figure 2Model of the role of neuronal chemokine (FKN) and neuronal cytokine (IL-34) in microglial phagocytosis and neuroprotection. Neuronal cells primary produce chemokine fractalkine (CX3CL1; FKN) and cytokine IL-34. Microglia predominantly express its receptor, CX3CR1, and colony-stimulating factor 1 receptor (CSF1R). Soluble form of FKN (sFKN) is secreted from damaged neurons and promotes microglial phagocytosis of neuronal debris through the release of MFG-E8. sFKN also induces the expression of the antioxidant enzyme HO-1 in microglia via Nrf2 recruitment and activation of the JNK MAPK signaling pathway. The neuroprotective effects of sFKN are also mediated in part by activation of ERK MAPK, although the downstream signaling pathway has not yet been elucidated. IL-34 promoted microglial proliferation and clearance of Aβ which mediates insulin-degrading enzyme (IDE) expression. Therefore, sFKN and IL-34 may be an intrinsic neuroprotectant for damaged yet surviving neurons.